2026-04-17T11:33:03Zhttps://recercat.cat/oai/request
oai:recercat.cat:2445/1115252025-12-05T05:45:42Zcom_2072_1057col_2072_478824col_2072_478858col_2072_478917col_2072_478921
RECERCAT author García-Albéniz, Xavier author Gallego, Rosa author Hofhteinz, Ralf Dieter author Fernández Esparrach, Glòria author Ayuso Colella, Juan Ramón author Bombí, Josep Antoni author Conill, Carles author Cuatrecasas Freixas, Miriam author Delgado Rivilla, Salvadora author Ginès i Gibert, M. Àngels author Miquel Morera, Rosa author Pagès Llinàs, M. (Mario) author Pineda, Estela author Pereira, María Verónica author Sosa, Aarón author Reig Torras, Oscar author Victoria, Iván author Feliz, Luis author Lacy Fortuny, Antonio Ma. de author Castells Garangou, Antoni author Burkholder, Iris author Hochhaus, Andreas author Maurel Santasusana, Joan 2017-05-25T07:54:10Z2017-05-25T07:54:10Z2014-11-142017-05-25T07:54:11Z AIM: To evaluate the long-term results of conventional chemoradiotherapy and laparoscopic mesorectal excision in rectal adenocarcinoma patients without adjuvant therapy. METHODS: Patients with biopsy-proven adenocarcinoma of the rectum staged cT3-T4 by endoscopic ultrasound or magnetic resonance imaging received neoadjuvant continuous infusion of 5-fluorouracil for five weeks and concomitant radiotherapy. Laparoscopic surgery was planned after 5-8 wk. Patients diagnosed with ypT0N0 stage cancer were not treated with adjuvant therapy according to the protocol. Patients with ypT1-2N0 or ypT3-4 or N+ were offered 5-fluorouracil-based adjuvant treatment on an individual basis. An external cohort was used as a reference for the findings. RESULTS: One hundred and seventy six patients were treated with induction chemoradiotherapy and 170 underwent total mesorectal excision. Cancer staging of ypT0N0 was achieved in 26/170 (15.3%) patients. After a median follow-up of 58.3 mo, patients with ypT0N0 had five-year disease-free and overall survival rates of 96% (95%CI: 77-99) and 100%, respectively. We provide evidence about the natural history of patients with localized rectal cancer achieving a complete response after preoperative chemoradiation. The inherent good prognosis of these patients will have implications for clinical trial design and care of patients. CONCLUSION: Withholding adjuvant chemotherapy after complete response following standard neoadjuvant chemoradiotherapy and laparoscopic mesorectal excision might be safe within an experienced multidisciplinary team. cc-by-nc (c) García-Albéniz, X. et al., 2014 http://creativecommons.org/licenses/by-nc/3.0/es info:eu-repo/semantics/openAccess Càncer colorectal Radioteràpia Quimioteràpia del càncer Cirurgia laparoscòpica Estudi de casos Colorectal cancer Radiotherapy Cancer chemotherapy Laparoscopic surgery Case studies Adjuvant therapy sparing in rectal cancer achieving complete response after chemoradiation info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion